KNIGHT THERAPEUTICS INC (GUD.CA) Stock Price & Overview
TSX:GUD • CA4990531069
The current stock price of GUD.CA is 6.1 CAD. Today GUD.CA is down by -1.45%. In the past month the price increased by 3.39%. In the past year, price increased by 1.84%.
GUD.CA Key Statistics
- Market Cap
- 602.253M
- P/E
- N/A
- Fwd P/E
- 127.15
- EPS (TTM)
- -0.02
- Dividend Yield
- N/A
GUD.CA Stock Performance
GUD.CA Stock Chart
GUD.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GUD.CA. When comparing the yearly performance of all stocks, GUD.CA is a bad performer in the overall market: 67.25% of all stocks are doing better.
GUD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA. While GUD.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
GUD.CA Earnings
On November 6, 2025 GUD.CA reported an EPS of -0.02 and a revenue of 121.55M. The company missed EPS expectations (-692.08% surprise) and beat revenue expectations (12.49% surprise).
GUD.CA Forecast & Estimates
10 analysts have analysed GUD.CA and the average price target is 8.09 CAD. This implies a price increase of 32.66% is expected in the next year compared to the current price of 6.1.
For the next year, analysts expect an EPS growth of -409.73% and a revenue growth 20.16% for GUD.CA
GUD.CA Groups
Sector & Classification
GUD.CA Financial Highlights
Over the last trailing twelve months GUD.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 93.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| Debt/Equity | 0.11 |
GUD.CA Ownership
GUD.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.16 | 2.553B | ||
| CRON | CRONOS GROUP INC | 38.58 | 1.285B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.108B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.43 | 935.17M | ||
| DHT-U | DRI HEALTHCARE TRUST | 5.1 | 642.517M | ||
| WEED | CANOPY GROWTH CORP | N/A | 569.809M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 423.64M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 17.64 | 364.538M | ||
| TSND | TERRASCEND CORP | N/A | 327.378M | ||
| HITI | HIGH TIDE INC | 23.98 | 290.916M | ||
| ACB | AURORA CANNABIS INC | 59.28 | 271.641M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.6 | 263.504M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About GUD.CA
Company Profile
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
Company Info
IPO: 2014-02-28
KNIGHT THERAPEUTICS INC
3400 De Maisonneuve Blvd W
MONTREAL QUEBEC H3Z 3B8 CA
CEO: Jonathan Ross Goodman
Employees: 745
Phone: 15144844483
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you describe the business of KNIGHT THERAPEUTICS INC?
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
What is the current price of GUD stock?
The current stock price of GUD.CA is 6.1 CAD. The price decreased by -1.45% in the last trading session.
Does GUD stock pay dividends?
GUD.CA does not pay a dividend.
How is the ChartMill rating for KNIGHT THERAPEUTICS INC?
GUD.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does KNIGHT THERAPEUTICS INC have?
KNIGHT THERAPEUTICS INC (GUD.CA) currently has 745 employees.
What is the market capitalization of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a market capitalization of 602.25M CAD. This makes GUD.CA a Small Cap stock.